Developing new osteoarthritis treatments has proven to be a challenge, with no major breakthroughs in the past 40 years. Deeper knowledge about the pathophysiology of osteoarthritis is paving the way for the development of new innovative products – including cell and gene therapies -- to treat, and potentially even cure, OA.
Join our panel of PharmaLex and external experts as they describe the scientific journey into OA pathophysiology, possible paths for developing products in the field and how integrated product development can be applied to the development process to optimize and de-risk R&D.
Prof Yves Henrotin, is a renowned expert in osteoarthritis and founder of Artialis, a company focused on biomarker-based solutions to support product development in musculoskeletal disorders.
Dr. Patrick Larcier has worked in drug development and regulatory affairs for 30 years, at large pharmaceutical companies, at CROs and in consulting. Until April 2022, he led drug development and pharmacovigilance activities for France and Benelux; he now provides support for PharmaLex’s growing EU and U.S. business.
Dr. Christelle Boileau has more than 20 years of experience in drug development, largely focused on fundamental and translational research. At PharmaLex France, she leverages her experience in early-stage development and provides project and program management support.